<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520452</url>
  </required_header>
  <id_info>
    <org_study_id>1716NRC</org_study_id>
    <nct_id>NCT03520452</nct_id>
  </id_info>
  <brief_title>Effect of Chlorogenic Acids on the Human Vasculature</brief_title>
  <official_title>Effect of Chlorogenic Acids on the Human Vasculature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates effects of different doses of chlorogenic acids on vascular health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been suggested that consumption of food rich in chlorogenic acids can help to improve
      vascular health, measured by flow mediated dilation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy by oral administration of chlorogenic acid in improving endothelial function</measure>
    <time_frame>24 hours</time_frame>
    <description>The primary outcome will be the average change from baseline (i.e. predose) in the %Flow Mediated Dilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of the different chlorogenic acid metabolites</measure>
    <time_frame>24 hours</time_frame>
    <description>link for endothelial function improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve of the concentration/time curve</measure>
    <time_frame>24 hours</time_frame>
    <description>Area Under Curve of the concentration/time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 hours</time_frame>
    <description>link for endothelial function improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>elimination half-life.</measure>
    <time_frame>24 hours</time_frame>
    <description>link for endothelial function improvement</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood concentrations in plasma.</measure>
    <time_frame>24 hours</time_frame>
    <description>Blood concentrations in plasma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety of the investigational product</measure>
    <time_frame>from first dose till last visit</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>302 mg green coffee extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Green coffee extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>604 mg green coffee extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Green coffee extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>906 mg green coffee extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Green coffee extract</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Green coffee extract</intervention_name>
    <description>Reconstituted in water and given to subjects</description>
    <arm_group_label>302 mg green coffee extract</arm_group_label>
    <arm_group_label>604 mg green coffee extract</arm_group_label>
    <arm_group_label>906 mg green coffee extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or postmenopausal female healthy volunteers aged 45-65 years old

          2. Willing and able to sign written informed consent prior to trial entry

          3. Healthy as determined by the medical history and physical examination

        Exclusion Criteria:

          1. Premenopausal women

          2. Current smokers

          3. Abnormal blood pressure, defined as follow: systolic &lt;90 or &gt;140 mmHg and diastolic
             &lt;60 or &gt;90 mmHg

          4. Regular consumption of cholesterol-lowering medication

          5. Regular consumption of antihypertensive medication

          6. Regular consumption of any vasoactive medication that cannot be discontinued for at
             least 4 half-lives before the FMD assessment

          7. Any food allergies

          8. Any intakes of multivitamin-tablets and other supplemental compounds within 10 days of
             the study start and throughout the study

          9. Inability to refrain from coffee/tea and alcohol consumption for 12 h prior to study
             visits

         10. Acute or chronic major psychiatric illness or other major illness that in the opinion
             of the investigator would make the subjects' participation in the study unsafe or
             prevent them from fully complying with the study procedures

         11. Use of medication to treat psychiatric illness (depression) within 3 months prior to
             the study

         12. Recent significant weight loss or gain (&gt;6% of body weight) in the past 3 months

         13. Body mass index (BMI) outside 18-32 kg/m2 range

         14. Alcohol intake &gt; 280g/week (21-28 glasses per week)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Tan</last_name>
    <role>Study Chair</role>
    <affiliation>Nestlé</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Tan</last_name>
    <phone>+65 6635 5840</phone>
    <email>leslie.tan@rdsg.nestle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Western Australia</name>
      <address>
        <city>Crawley</city>
        <state>Perth</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

